

2022

2019 2021

2019 2021

1	2019-01-07-0 0-01-E00036			2019	
2	2019-01-07-0 0-01-E00059			2019	
3	2019-01-07-0 0-01-E00074	Trem100 /	TRPV1/A1 ---	2019	
4	2021-01-07-0 0-02-E00090			Christophe r Heeschen	2021
5	2021-01-07-0 0-02-E00091				2021
6	2021-01-07-0 0-02-E00139	mtDNA			2021

1.

/

"

/ /

"

First-in-class

4 4 2

1

2

1 . 2022

7

3

10

2 .

1

1

1

3.

		2022	2022 2022	2022
2019		60	60	100%

1.

17

6

4

2

5

40

2010

"

"

2013

"

"

6

1

1

SCI

30

16

10 7

20

13.5

4

El sevi er

"

"

"

"

2

Wit

2022

7

IF>5

3

2

1 1 1 1 1 1

" " 1 " " 1 "

"

3.

		2022	2022	2022
			2022	
2019		60	60	100%

Trem100 TRPV1/A1 --- /

1.

9 79 30 400 400

11 400 SCI 140 400

JCI Advanced Science BJA Pain Stroke Science Translational Medicine Nature  
Communications Anesthesiology

1 2021 1 "

" " " " " " "

" " 7 3

2.

2022

TRPV1/A1

2022 SCI 7

The Journal of Clinical Investigation

19.456 2 2

3.

		2022	2022	2022
			2022	2022
2019	Trem100 TRPV1/A1 ---	60	59.86	99.77%

	/			
--	---	--	--	--

Christopher Heeschen

1.

Christopher Heeschen

20

Engl J Med, Nat Med, Nat Methods, Cancer

Cell, Cell Stem Cell, Cell Metabolism, J Exp Med, J Clin Invest, Lancet, PNAS

167

35,000

h-

77 Christopher Heeschen

2019 10

1

2

4

2

2

2.

in silico

CSCs

Smart-seq3

2021

1 2021

1 2022

1

3.

		2022	2022	2022
			2022	
2021		105.00	15.82	15%

1.

Nature Communication Lancet Oncol.

Blood Nature Genetics

2

2

2

1

2

2

2

3

3

2.

ATO

TKI

ATO

BCR-ABLWT

BCR-ABL T315I

BCR-ABL1

As4S4

A BCR-ABL ALL I I A  
 PDX T315I  
 TKI Ph+ALL DNR  
 Ba/F3-BA Tom71 Sup-b15 DNR TKI  
 SA- -gal + RNAseq  
 Ph+

ATO

3.

		2022	2022	2022
			2022	
2021		105	47.595785	45.3%

mt DNA

1.

WBCR16

mt DNA

1

1 4 3 4  
 2

1 3 3 3  
 3

3.

		2022	2022	2022
			2022	
2021	mt DNA	35	10.9895	31%

2023 2 15 -2023 2 22

63846590-776351/15802135763

2023 2 15